Animal models and methods for analysis of lipid metabolism and screening of pharmaceutical and pesticidal agents that modulate lipid metabolism
CA 2373628 A1 · Owner: Exelixis Inc. · Inventors: Elson, Sarah; Stout, Thomas J.; Keegan, Kevin Patrick
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Drosophila melanogaster and <i>C. elegans</i> that have been genetically modified to express or mis-express proteins involved in the sterol regulatory element binding protein (SREBP) pathway are described. These genetically modified animal models have identifiable phenotypes that make them useful in assays for studying lipid metabolism, other genes implicated in lipid metabolism, and compounds capable of modulating lipid metabolism pathways. Methods for studying lipid metabolism in living mematodes using fluorescently labeled fatty acid conjugates, such BODIPYTM fatty acid conjugates are also , described. Novel SREBP pathway nucleic acid and protein sequences are also described.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 8, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended June 8, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 8, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.